Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 2, 2008, Pages 173-184

  Ki, Vincent ^a,c   Rotstein, Coleman ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Bacterial; Infections; Management; Skin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFALEXIN; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; DOXYCYCLINE; ENDOTOXIN; ERTAPENEM; EXOTOXIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ASPIRATION; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; BLOOD CULTURE; CLINICAL FEATURE; CLOSTRIDIUM; COMPUTER ASSISTED TOMOGRAPHY; CORYNEBACTERIUM; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; ECOLOGY; EDEMA; EMERGENCY TREATMENT; ENTEROBACTERIACEAE; ENTEROCOCCUS; ERYTHEMA; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL PATIENT; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INCISION; INFECTION RISK; LUMBAR PUNCTURE; MEDICAL EXAMINATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PREVALENCE; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; RADIODIAGNOSIS; REVIEW; SKIN INFLAMMATION; SKIN MANIFESTATION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PYOGENES; SURGICAL DRAINAGE; TISSUE CULTURE; TOXIC SHOCK SYNDROME; VIBRIO VULNIFICUS;

EID: 44449127258     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/846453     Document Type: Review

References (45)

1. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004;350:904-12.
2. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA; Expert panel on managing skin and soft tissue infections. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52:i3-17.
3. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406. (Errata in 2005;41:1830, 2006;42:1219).
4. Elston DM. Optimal antibacterial treatment of uncomplicated skin and skin structure infections: Applying a novel treatment algorithm. J Drugs Dermatol 2005;4(6 Suppl):s15-9.
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
6. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002;347:2039-45.
7. Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006;134:293-9.
8. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005;5:501-13.
9. Baddour LM. Epidemiology, clinical features, and diagnosis of cellulitis, 〈http://www.utdol.com/utd/content/topic.do?topicKey=skin.inf/ 11185&selectedTitle=1150&source=searc_result2008〉 (Version current at February 12, 2008).
10. Cox NH. Management of lower leg cellulitis. Clin Med 2002;2:23-7.
11. Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, et al. Risk factors for acute cellulitis of the lower limb: A prospective case-control study. Clin Infect Dis 2005;41:1416-22.
12. Horowitz Y, Sperber AD, Almog Y. Gram-negative cellulitis complicating cirrhosis. Mayo Clin Proc 2004;79:247-50.
13. Todar K. The bacterial flora of humans. 〈http:// textbookofbacteriology.net/normalflora.html〉 (Version current at February 12, 2008).
14. Rennie RP, Jones RN, Mutmck AH; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287-93.
15. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumherg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17.
16. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311-20.
17. Eady EA, Cove JH. Staphylococcal resistance revisited: Community-acquired methicillin resistant Staphylococcus aureus - an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24.
18. Moroney SM, Heller LC, Arbuckle J, Talavera M, Widen RH. Staphylococcal cassette chromosome mec and Panton-Valentine leukocidin characterization of methicillin-resistant Staphylococcus aureus clones. J Clin Microbiol 2007;45:1019-21.
19. McAdam AJ, Sharpe AH. Infectious diseases - bacterial infections. In: Kumar V, Abbas AK, Fausto N, eds. Robbins & Cotran Pathologic Basis of Disease. Philadelphia: Elsevier Inc, 2005:371-96.
20. Nauta RJ. A radical approach to bacterial panniculitis of the abdominal wall in the morbidly obese. Surgery 1990;107:134-9.
21. Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect 2005;133:383-91.
22. Acute and chronic inflammation. In: Kumar V, Abbas AK, Fausto N, eds. Robbins & Cotran Pathologic Basis of Disease. Philadelphia: Elesvier Inc, 2005:47-86.
23. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35.
24. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000;16:S75-83.
25. Lipsky BA, Berendt AR, Deery HG, et al; Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
26. Falagas ME, Vergidis PI. Narrative review: Diseases that masquerade as infectious cellulitis. Ann Intern Med 2005;142:47-55.
27. Hook EW III, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295-7.
28. Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004;21:705-9.
29. Senneville E, Melliez H, Bertrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: Concordance with ulcer swab cultures. Clin Infect Dis 2005;42:47-62.
30. Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988;26:401-4.
31. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990;150:1907-12. (Erratum in 1991;151:244).
32. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-26.
33. Tsai CC, Lai CS, Yu ML, Chou CK, Lin SD. Early diagnosis of necrotizing fasciitis by utilization of ultrasonography. Kaohsiung J Med Sci 1996;12:235-40.
34. Howe L, Jones NS. Guidelines for the management of periorbital cellulitis/abscess. Clin Otolaryngol Allied Sci 2004;29:725-8.
35. Berkow SG. A method of estimating the extensiveness of lesions, burns and scalds, based on surface area proportions. Arch Surg Lond 1924;8:138-48.
36. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63:1459-80.
37. Rosser WW, Pennie RA, Pila NJ; The Anti-Infective Review Panel. Anti-Infective Guidelines for Community-Acquired Infections. Toronto: MUMS Guideline Clearinghouse, 2005.
38. Falagas ME, Matthaiou DK, Vardakas KZ. Fluoroquinolones vs beta-lactams for empirical treatment of immunocompetent patients with skin and soft tissue infections: A meta-analysis of randomized controlled trials. Mayo Clin Proc 2006;81:1553-66.
39. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteremia? A meta-analysis. Lancet Infect Dis 2004;4:519-27.
40. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;(1):CD001090.
41. Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 2006;17(Suppl):1B-24B.
42. Jewesson PJ. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995;6(Suppl):11A-6A.
43. Desai M, Franklin BD, Holmes AH, et al. A new approach to treatment of resistant gram-positive infections: Potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis 2006;6:94.
44. Hanakawa Y, Schecter NM, Lin C, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002;110:53-60.
45. Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: Structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004;68:981-1003. (Erratum in 2004;68:A4).